---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-079452"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:13:39.623062+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029

## Summary
- Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
- Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.
- Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.
- PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.
- CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026.

## SEC filing metadata
- accession: 0001193125-26-079452
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/0001193125-26-079452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-079452
- JSON: https://secwatch.observer/filing/0001193125-26-079452.json
- Plain text: https://secwatch.observer/filing/0001193125-26-079452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.